Auszug
Bei fortgeschrittenem Organversagen von Niere, Herz, Leber oder Lunge stellt eine Organtransplantation meist das einzige kurative Therapieverfahren dar. Auch eine Knochenmarktransplantation wird bei sonst unheilbaren Leukämien oder Lymphomen eingesetzt. Nach Organtransplantation treten bei 30–60% der Patienten neurologische Komplikationen auf. Differenzialdiagnostisch müssen vorbestehende, durch die Grunderkrankung bedingte, Störungen von intraoperativen Komplikationen, von metabolisch bedingten neurologischen Störungen und von Nebenwirkungen der notwendigen immunsuppressiven Medikation abgegrenzt werden. Immunsuppressiva können dabei sowohl eine direkte Neurotoxizität als auch indirekt vermehrt Infektionen des Zentralnervensystems (ZNS) und sekundäre ZNS-Malignome verursachen. Während metabolische Enzephalopathien oder opportunistische ZNS-Infektionen bei allen Patienten nach Transplantation etwa gleich häufig auftreten können, sind andere neurologische Syndrome für bestimmte Organtransplantationen typisch.
Chapter PDF
Similar content being viewed by others
Literatur
Antonini G, Ceschin V, Morino S, Fiorelli M, Gragnani F, Mengarelli A, Iori AP, Arcese W (1998) Early neurologic complications following allogeneic bone marrow transplant for leukemia: A prospective study. Neurology 50:1441–1445
Appignani BA, Bhadelia RA, Blacklow SC, Wang AK, Roland SF, Freeman RB, Jr. (1996) Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. Am J Roentgenol 166:683–688
Ardizzone G, Arrigo A, Schellino MM, Stratta C, Valzan S, Skurzak S, Andruetto P, Panio A, Ballaris MA, Lavezzo B, Salizzoni M, Cerutti E (2006). Neurological complications of liver cirrhosis and orthotopic liver transplant. Transplant Proc 38:789–792
Beresford TP (2001) Neuropsychiatric complications of liver and other solid organ transplantation. Liver Transpl 7: S36–45
Blanco R, De Girolami U, Jenkins RL, Khettry U (1995) Neuropathology of liver transplantation. Clin Neuropathol 14:109–117
Bleggi-Torres LF, de Medeiros BC, Werner B, Neto JZ, Loddo G, Pasquini R, de Medeiros CR (2000) Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant 25:301–307
Campellone JV, Lacomis D (1999) Neuromuscular disorders. In: Neurologic complications in organ transplant recipients. Wijdicks EFM (Hrsg), Butterworth Heinemann, Boston, pp. 169–192
Conti DJ, Rubin RH (1988) Infection of the central nervous system in organ transplant recipients. Neurol Clin 6:241–260
Coplin WM, Cochran MS, Levine SR, Crawford SW (2001) Stroke after bone marrow transplantation: frequency, aetiology and outcome. Brain 124:1043–1051
de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ (2000) Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry 68:36–40
Faraci M, Lanino E, Dini G, Fondelli MP, Morreale G, Dallorso S, Manzitti C, Calevo MG, Gaggero R, Castagnola E, Haupt R (2002) Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology 59:1895–1904
Ferrari U, Empl M, Kim KS, Sostak P, Forderreuther S, Straube A (2005) Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms. Headache 45:211–214
Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338:1741–1751
Forgacs B, Merhav HJ, Lappin J, Mieles L (2005). Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 37:1912–1914
Furlan AJ, Sila CA, Chimowitz MI, Jones SC (1992) Neurologic complications related to cardiac surgery. Neurol Clin 10:145–166
Gallardo D, Ferra C, Berlanga JJ, Banda ED, Ponce C, Salar A, Alonso E, Espannol I, Riu C, Granena A (1996) Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 18:1135–1139
Goldstein LS, Haug MT, Perl J, Perl MK, Maurer JR, Arroliga AC, Mehta AC, Kirby T, Higgins B, Stillwell PC (1998) Central nervous system complications after lung transplantation. J Heart Lung Transplant 17:185–191
Graus F, Saiz A, Sierra J, Arbaiza D, Rovira M, Carreras E, Tolosa E, Rozman C (1996) Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia: a comparative study. Neurology 46:1004–1009
Gross ML, Sweny P, Pearson RM, Kennedy J, Fernando ON, Moorhead JF (1982) Rejection encephalopathy. An acute neurological syndrome complicating renal transplantation. J Neurol Sci 56:23–34
Guarino M, Benito-Leon J, Decruyenaere J, Schmutzhard E, Weissenborn K, Stracciari A; EFNS (2006). EFNS guidelines on management of neurological problems in liver transplantation. Eur J Neurol 13:2–9
Hou J, Major E (2005). Management of infections by the human polyomavirus JC: past, present and future. Expert Rev Anti Infect Ther 3:629–40
Ide K, Ohdan H, Tahara H, Ishiyama K, Shishida M, Irei T, Ohira M, Tashiro H, Itamoto T, Asahara T (2007) Possible therapeutic effect of lipid supplementation on neurological complications in liver transplant recipients. Transpl Int 20:632–635
Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567–1601
Müller-Felber W, Landgraf R, Scheuer R, Wagner S, Reimers CD, Nusser J, Abendroth A, Illner WD, Land W (1993) Diabetic neuropathy 3 years after successful pancreas and kidney transplantation. Diabetes 42:1482–1486
Niedobitek G, Mutimer DJ, Williams A, Whitehead L, Wilson P, Rooney N, Young LS, Hubscher SG (1997) Epstein-Barr virus infection and malignant lymphomas in liver transplant recipients. Int J Cancer 73:514–520
Nymann T, Hathaway DK, Bertorini TE, Shokouh Amiri MH, Gaber AO (1998) Studies of the impact of pancreas-kidney and kidney transplantation on peripheral nerve conduction in diabetic patients. Transplant Proc 30:323–324
Pace MT, Slovis TL, Kelly JK, Abella SD (1995) Cyclosporin A toxicity: MRI appearance of the brain. Pediatr Radiol 25:180–183
Padovan CS, Yousry TA, Schleuning M, Holler E, Kolb HJ, Straube A (1998) Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation. Ann Neurol 43:627–633
Parizel PM, Snoeck HW, van den Hauwe L, Boven K, Bosmans JL, Van Goethem JW, Van Marck EA, Cras P, De Schepper AM, De Broe ME (1997) Cerebral complications of murine monoclonal CD3 antibody (OKT3): CT and MR findings. Am J Neuroradiol 18:1935–1938
Patchell RA (1988) Primary central nervous system lymphoma in the transplant patient. Neurol Clin 6:297–303
Patchell RA (1994) Neurological complications of organ transplantation. Ann Neurol 36:688–703
Perez-Miralles F, Sanchez-Manso JC, Almenar-Bonet L, Sevilla-Mantecon T, Martinez-Dolz L, Vilchez-Padilla JJ (2005) Incidence of and risk factors for neurologic complications after heart transplantation. Transplant Proc 37:4067–4070
Pomeranz S, Naparstek E, Ashkenazi E, Nagler A, Lossos A, Slavin S, Or R (1994) Intracranial haematomas following bone marrow transplantation. J Neurol 241:252–256
Ponticelli C, Campise MR (2005) Neurological complications in kidney transplant recipients. J Nephrol. 18:521–528
Saner F, Gu Y, Minouchehr S, Ilker K, Fruhauf NR, Paul A, Radtke A, Dammann M, Katsarava Z, Koeppen S, Malagó M, Broelsch CE (2006). Neurological complications after cadaveric and living donor liver transplantation. J Neurol 253:612–617
Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A (2003) Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 60:842–848
Swinnen LJ (1997) Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation. Leuk Lymphoma 28:89–101
Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, Han S, Harrison ME, Stravitz TR, Muñoz S, Brown R, Lee WM, Blei AT (2005). Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 11:1581–1589
Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA (1994) FK506-induced neurotoxicity in liver transplantation. Ann Neurol 35:498–501
Wijdicks EF, Wiesner RH, Krom RA (1995) Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 45:1962–1964
Wilson JR, Conwit RA, Eidelman BH, Starzl T, Abu Elmagd K (1994) Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 17:528–532
Wolkowitz OM, Reus VI, Canick J, Levin B, Lupien S (1997) Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann N Y Acad Sci 823:81–96
Zentner J, Buchbender K, Vahlensieck M (1995) Spinal epidural lipomatosis as a complication of prolonged corticosteroid therapy. J Neurosurg Sci 39:81–85
Literatur
Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides fpor hepatic encephalopathy: systemic review of randomised trials. BMJ 328: 1046–1050.
Basler T, Meier-Hellmann A, Bredle D, Reinhart K (2002) Amino acid imbalance early in septic encephalopathy. Intensive Care Med 28:293–298.
Bleck TP, Smith MC, Pierre-Louis SJ, Jares JJ, Muray J, Hansen CA (1993) Neurologic complications of critical medical illnesses. Crit Care Med 21:98–103.
Bogdanski R, Blobner M, Hanel F, Kochs E (1999) Die septische Enzephalopathie. Anaesthesiol Intensivmed Notfallmed Schmerzther 34:123–130.
Bolton CF, Young GB, Zochodne DW (1993) The neurological complications of sepsis. Ann Neurol 33:94–100
Bolton CF, Young-GB (1989) Neurological complications in critical ill patients. In: Aminoff MJ. Neurology and General Medicine. New York. Churchill Livingstone 713–729.
Boon P, de Reuck J, Achten E, de Bleecker J (1991) Pancreatic encephalopathy. A case report and review of the literature. Clin Neurol Neurosurg 93:137–141.
Brouns R, De Deyn PP (2004) Neurological complications in renal failure: a review.
Burn DJ, Bates D (1998) Neurology and the kidney. J Neurol Neurosurg Psychiatry 65:810–821.
Butterworth RF (2000) Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Op Neurol 13:721–727.
Chan C, Fryer J, Herkes G, Prelog K, Harrington T (2003) Fatal brain stem event complicating acute pancreatitis. J Clin Neurosc 10:351–358.
Chen R, Young GB (1996) Metabolic encephalopathies. Ballieres Clinical Neurology 5:577–598.
Eggers V, Schilling A, Kox WJ, Spies C (2003) Septische Enzephalopathie. Anaesthesist 52:294–303.
Ferenci P (2001) Hepatische Enzephalopathie. Dtsch Med Wochenschr 126Suppl 1:S76–80.
Finsterer J (2006) Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 114; 217–238.
Garg RK (2001) Posterior leukoencephalopathy syndrome. Postgrad Med J 77:24–28.
Hamann GF (2001) Bedeutung von Störungen des Elektrolyt-und Wasserhaushaltes in der Neurologischen Intensivmedizin. Akt Neurol 28:103–113.
Hartmann M et al.: Hashimoto-Enzephalopathie. Nervenarzt, 2000; 71: 489–494.
Hund E (2007) Septische Enzephalopathie. Dtsch Med Wschr 132: 322–324.
Kauppinen R (2005) Porphyrias. Lancet 365: 241–252.
Kramer L, Tribl B, Gendo A, Zauner G, Schneider B, Ferenci P, Madl C (2000) Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 31: 30–34.
Kunze K (2002) Metabolic encephalopathies. J Neurol 249:1150–1159.
Lewis M, Howdle PD (2003) The neurology of liver failure. Q J Med 96: 623–633.
Müllges W, Stoll G (2002) Hypoxisch-ischämische Enzephalopathie. Akt Neurol 29: 431–446.
Papadopoulos MC, Davies DC, Moss RF, Tighe D, Bennett ED (2000) Pathophysiology of septic encephalopathy: a review. Crit Care Med 28:3019–3024.
Schellinger PD et al.: Hepatische Enzephalopathie. Nervenarzt, 2003; 74: 1078–1087.
Schellinger PD et al.: Neurologische Komplikationen renaler Erkrankungen. Akt Neurol, 2003; 30: 375–381.
Schwarz S, Schwab S, Fabian CW, Schellinger P, Orberk E, Hund E (1997) Sepsis: unklare Bewußtseinstrübung als Initialsymptom. Klinik und Pathophysiologie der septischen Enzephalopathie. Nervenarzt 68:292–297.
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J (2006). Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 114; 1–7.
Stott VL, Hurrell MA, Anderson TJ (2005) Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 35:83–90
The Hypothermia After Cardiac Arrest Study Group (2002) Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. New Engl J Med 346:549–556.
Wijidicks EFM (1995) Neurology of critical illness. Contemporary Neurological Series No. 43; Philadelphia, FA Davis.
Young GB, Bolton CF, Archibald YM, Austin W, Wells GA (1992) The electroencephalogram in sepsis-associated encephalopathy. J Clin Neurophysiol 9:145–152.
Literatur
Baumgärtner GR (1988) Clonidine vs. Chlordiazepoxide in the management of acute alcohol withdrawal: A preliminary report. Southern Med J 81:56–60
Bjorkqvist SE, Isohanni M, Makela R, Malinen L (1976) Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentrre double-blind comparision with placebo. Acta Psychiatr. Scand 53:333–342.
Chung TI, Kim JS, Park SK, Kim BS, Ahn KJ, Yang DW (2003) Diffusion weighted MR imaging of acute Wernicke’s encephalopathy. Eur J Radiol 45:256–8
Day E, Bentham P, Callaghan R, Kuruvilla T, George S (2004) Thiamine for Wernicke-Korsakoff Syndrome in people at risk from alcohol abuse. Cochrane Database Syst Rev CD004033
Fauler J, Verner L (1993) The pharmakokinetics of clonidine in high dosage. Eur. J. Pharmacol 45:165–167
Galluci M, Bozzao A, Splendiani A, Masciocchi C, Passariello R (1990) Wernicke encephalopathy: MR findings in five patients. Am J Neuroradiol 11:887–892
Gerke P, Hapke U, Rumpf HJ, John U (1997) Alcohol-related diseases in general hospital patients. Alcohol Alcohol 32:179–84
Harding A, Halliday G, Caine D, Kril J (2000) Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. Brain 123:141–154
Harper C, Gold J, Rodrguez N, Perdices N (1989) The prevalence of the Wernicke-Korsakoff syndrome in Sydney, Australia: a prospective necropsy study. J Neurol Neurosurg Psychiatry 52:282–285.
He X, Sullivan EV, Stankovic RK, Harper CG, Pfefferbaum A (2007) Interaction of Thiamine Deficiency and Voluntary Alcohol Consumption Disrupts Rat Corpus Callosum Ultrastructure. Neuropsychopharmacology (im Druck)
Heinz A, Mann K (2001) Neurobiologie der Alkoholabhängigkeit. Dt Ärztebl 98:2279–2283
Hinze-Selche D, Weber, MM, Zimmermann U, Pollmächer T (2000) Die Thiaminbehandlung in der Neurologie und Psychiatrie. Fortschr Neurol Psychiat 68: 113–120
Holbrook AM, Crowther R, Lotter A, Cheng C, King D (1999) Metaanalysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 160:649–655
Kavuk I, Agelink MW, Gaertner T, Kastrup O, Doerfler A, Maschke M, Diener HC (2003) Wernicke’s encephalopathy: unusual contrast enhancement revealed by magnetic resonance imaging. Eur J Med Res 8:492–4
Lange-Asschenfeldt C, Müller MJ, Szegedi A, Anghelescu I, Klawe C, Wetzel H (2003) Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis. Eur Addict Res 9:1–7
Littleton J (1998) Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 22:13–24.
Malcolm R, Ballenger JC, Sturgis ET, Anton R (1989) Double-blind controlled trial comparing carbamazepine to oxacepam treatment of alcohol withdrawal. Am J Psychiatry 146:617–621
Mann KF (2000) Alkohol: Klinik und Behandlung (Kapitel 19) In: Helmchen H, Henn F, Lauter H, Sartorius N, Hrsg. Psychiatrie der Gegenwart, 4. Aufl., Band 6: Erlebens-und Verhaltensstärungen, Abhöngigkeit und Suizid 511–529
Maschke M, Weber J, Bonnet U, Dimitrova A, Bohrenkamper J, Sturm S, Muller BW, Gastpar M, Diener HC, Forsting M, Timmann D (2005) Vermal atrophy of alcoholics correlate with serum thiamine levels but not with dentate iron concentrations as estimated by MRI. J Neurol 252:704–11
Maschke M, Hansen HC, Müller T, Pfausler B, Tiecks F, Schuchardt V. Alkoholdelir. In: Diener HC, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; in Druck
Maschke M, Jahn K, Thier P. Alkoholfolgekrankheiten. In: Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. 5te Auflage, Kohlhammer Verlag, Stuttgart, Berlin, Köln (in Druck)
Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction 25. Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278:144–51
Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, Jara G, Kasser C, Melbourne J; Working Group on the Management of Alcohol Withdrawal Delirium, Practice Guidelines Committee, American Society of Addiction Medicine. (2004) Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 164:1405–12
Mc Grath SD (1975) A controlled trial of clomethiazole and chlordiazepoxide in the treatment of the acute withdrawal phase of alcoholism. Conference on alcoholism. Longman, London, 81–90
Ntais C, Pakos E, Kyzas P, Ioannidis JP (2005) Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 20:CD005063
Palmstierna T (2001) A model for predicting alcohol withdrawal delirium. Psychiatr Serv 52:820–3
Pitkin SR, Savage LM (2001) Aging potentiates the acute and chronic neurological symptoms of pyrithiamine-induced thiamine deficiency in the rodent. Behav Brain Res 119:167–77
Polycarpou A, Papanikolaou P, Ioannidis JP, Contopoulos-Ioannidis DG (2005) Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 20:CD005064
Ritola E, Malinen L (1981) A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand 64:254–259
Rommelspacher H, Schmidt LG, Helmchen H (1991) Pathobiochemistry and Pharmacotherapy of alcohol withdrawal. Nervenarzt 62:649–657
Sechi G, Serra A (2007) Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 6:442–55
Seifert J, Peters E, Jahn K, Metzner C, Ohlmeier M, te Wildt B, Emrich HM, Schneider U (2004) Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance—a pilot study. Addict Biol 9:43–51
Spies CD, Dubisz N, Neumann T, Blum S, Muller C, Rommelspacher H, Brummer G, Specht M, Sanft C, Hannemann L, Striebel HW, Schaffartzik W (1996) Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med 24:414–22
Spies CD, Otter HE, Huske B, Sinha P, Neumann T, Rettig J, Lenzenhuber E, Kox WJ, Sellers EM (2003) Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. Intensive Care Med 29:2230–8
Sullivan EV, Pfefferbaum A (2001) Magnetic resonance relaxometry reveals central pontine abnormalities in clinically asymptomatic alcoholic men. Alcohol Clin Exp Res 25:1206–12
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWAAr). Br J Addict 84:1353–1357.
Surges R, Beck S, Niesen WD, Weiller C, Rijntjes M (2007) Sudden bilateral blindness in Wernicke’s encephalopathy: Case report and review of the literature. J Neurol Sci (in Druck)
Thomson AD, Marshall EJ (2006) The treatment of patients at risk of developing Wernicke’s encephalopathy in the community. Alcohol Alcohol 41:159–67
Tong GM, Rude RK (2005) Magnesium deficiency in critical illness. J Intensive Care Med 20:3–17
Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 155:726–32
Wetterling T, Kanitz R-D, Besters B, Fischer D, Zerfass B, John U, Spranger H, Driessen M (1997) A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol 32:753–760.
Literatur
Aggarwal A, Esler MD, Lambert GW, Hastings J, Johnston L, Kaye DM (2002) Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation 105: 1031–1033
Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ (1981) Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control. Science 213: 220–222
Atkinson PPA, Atkinson JLD (1996) Spinal schock. Mayo Clin Proc 71: 384–389
Benarroch EE (1996) Central nervous system disorders. In: Robertson D, Low PA, Polinsky RJ (Hrsg) Primer on the autonomic nervous system. Academic Press, San Diego New York Boston London Sydney Tokyo Toronto, S 226–229
Biswas AK, Scott WA, Sommerauer JF et al. (2000) Heart rate variability after acute traumatic brain injury in children. Crit Care Med 28. 3907–12
Brignole M, Menozzi C (1997) Methods other than tilt testing for diagnosing neurocardiogenic (neurally mediated) syncope. Pace 20: 795–800
Buchanan N, Cane RD, Wolfson G, DeAndrade M (1979) Autonomic dysfunction in tetanus: the effects of a variety of therapeutic agents, with special reference to morphine. Intens Care Med 5: 65–68
Byer EB, Ashman R, Toth LA (1947) Electrocardiograms with large upright T-waves and long QT-intervals. American Heart Journal 33: 796–806
Chalela J (2001) Pearls and Pitfalls in the Intensive Care: Management of Guillain-Barré Syndrome. Semin Neurol 21: 399–406
Cechtto DF, Chen SJ (1992) Hypothalamic and cortical sympathetic responses relay in the medulla of the rat. Am J Physiol 263: R544–552
Cheung RT, Hachinski V (2000) The insula and cerebogenic sudden death. Arch Neurol 57: 1685–1688
Dechan SC, Grant IS (1996) Haemodynamic changes in neurogenic pulmonary edema. Effect of dobutamine. Intensive Care Med 22: 672–678
Di Pasquale G, Pinelli G, Andreoli A, Manini G, Grazi P, Tognetti F (1987) Holter detection of cardiac arrhythmias in intracranial subarachnoid hemorrhage. Am J Cardiol 59: 596–600
Dimant J, Grob D (1977) Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. Stroke 8: 448–455
Englert D, Baumgarten FJ von, Gunreben G, Reifschneider G, Hassel W, Przuntek H (1985) Zur Herzschrittmacherindikation bei Polyradikulitis: Ein standardisiertes Verfahren für den Bulbusdruckversuch. In: Gänshirt H, Berlit P, Haack G (Hrsg) Verhandlungen der deutschen Gesellschaft für Neurologie. Springer, Berlin Heidelberg New York Tokyo S280–282
Ernst ME, Klepsen ME, Fouts M, Marangus MN (1997) Tetanus: pathophysiology and management. Ann Pharmacother 31: 1507–1513
Flachenecker P, Hartung HP, Reiners K (1997) Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study. Brain 120: 1885–1894
Flachenecker P, Reiners K: Twenty-four hour heart rate power spectrum for evaluation of autonomic dysfunction in GBS (1999) J. Neurol. Sci. 165:144–53
Flachenecker P, Müllges W, Wermuth P, Hartung HP, Reiners K (1996) Eyeball pressure testing in the evaluation of serious bradyarrhythmias in Guillain-Barré syndrome. Neurology 47: 102–108
Flachenecker P, Toyka KV, Reimers K (2001) Herzrhythmusstörrungen beim Guillain-Barré-Syndrom: Eine Übersicht zur Diagnostik einer seltenen aber potenziell lebensbedrohlichen Komplikation. Nervenarzt 72: 610–617
Goldstein DS (1979) The electrocardiogram in stroke: relationship to pathophysiological type and comparison with prior tracings. Stroke 10: 253–259
Guttmann L, Whitteridge D (1947) Effect of bladder distension on autonomic mechanisms after spinal cord injury. Brain 70: 361–404
Hachinski VC (1993) The clinical problem of brain and heart. Stroke 24: 1–2
Haji-Michael PG, Vincent JL, Degaute JP et al. (2000) Power spectral analysis of cardiovascular variability in critically ill neurosurgical patients 28: 2578–83
Hamann G, Haass A, Schimirgk K (1993) Betablockade in acute aneurysmal subarachnoid haemorrhage. Acta Neurochir 121: 119–122
Hennersdorf MG, Perings C, Niebich V et al. (2000) Chemoreflex sensitivity in patients with survived sudden cardiac arrest and prior myocardial infarction (2000) Pacing Clin Electrophys 23: 457–62
Hilz MJ (2002) Quantitative autonomic functional testing in clinical trials. In: Brown WF, Bolton CF, Aminoff MJ, eds.: Neuromuscular Function and Disease. Basic, clinical and electrodiagnostic aspects. WB Saunders, Philadelphia, USA, Volume 2; 1899–1929
Hilz MJ, Devinsky O, Doyle W, Mauerer A, Dutsch M (2002) Decrease of cardiovascular modulation after temporal lobe epilepsy surgery. Brain 125: 985–995
Hilz MJ, Stemper B, Neundorfer B (2000) Physiology and methods for studying the baroreceptor reflex. Fortschr Neurol Psychiatr. 68:37–47
James P, Ellis CJ, Whitlock RM, McNeil AR, Henley J, Anderson NE (2000) Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. Br Med J 320: 1502–1504
Korpelainen JT, Sotaniemi KA, Huikuri HV, Myllylä VV (1996) Abnormal heart rate variability as a manifestation of autonomic dysfunction in hemisphereic brain infarction. Stroke 27: 2059–2063
Lagerkranser M, Pehrrson K, Sylvon C (1982) Neurogenic pulmonary edema: A review of the pathophysiology and clinical and therapeutic implications. Acta Med Scand 212: 267–271
Lichtenfeld P (1970) Autonomic dysfunction in the Guillain-Barre syndrome. AmJ Med 50: 772–780.
Lown B, Levine SA (1961) The carotid sinus. Clinical value of its stimulation. Circulation 23: 766–789
Masuda T, Sato K, Yamamoto S, Matsuyama N, Shimohama T, Matsunaga A, Obuchi S, Shiba Y, Shimizu S, Izumi T (2002) Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke 33: 1671–1676
Ohtsuka T, Hamada M, Kodama K, Sasaki O, Suziki M, Hara Y, Shigematsu Y, Hiwada K (2000) Neurogenic stunned myocardium. Circulation 101: 2122–2124
Oppenheimer SM, Cechetto DF, Hachinski VC (1990) Cerebrogenic cardiac arrhythmias. Cerebral electrocardiographic influences and their role in sudden death. Arch Neurol 47: 513–519
Parekh N, Venkatesh B, Cross D, Leditschke A, Atherton J, Miles W, Winning A, Clague A, Rickard C (2000) Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. J Am Coll Cardiol 36: 1328–1335
Pfeiffer G (1999) Dysautonomie bei Giullain-Barré-Syndrom. Nervenarzt 70: 136–148.
Robertson D, Low PA, Polinsky RJ (1996) Primer on the autonomic nervous system. Academic press, San Diego New York Boston London Sydney Tokyo Toronto
Robinson RF, Nahata MC (2003) Management of botulism. Ann Pharmacother 37: 127–131
Robinson TG, James M, Youde J, Panerai R, Potter J (1997) Cardiac baroreceptor sensitivity is impaired after acute stroke. Stroke 28: 1671–1676
Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B (2001) Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 57: 833–838
Schmidt HB, Werdan K, Müller-Werdan U (2001) Autonomic dysfunction in the ICU patient. Curr Opin Crit Care 7: 314–22
Schuchert A, Behrens G, Meinertz T (1999) Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke. Pacing Clin Electrophysiol 22: 1082–1084
Schuri U, von Cramon D (1982) Electrodermal response patterns in neurological patients with disturbed vigilance. Behav Brain Res 4: 95–102.
Singh NK, Ljaiswal AK, Misra S, Srivastava PK (1987) Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications. Acta Neurol Scand 75: 101–105
Tokgozoglu SL, Batur MK, Topuoglu MA, Saribas O, Kes S, Oto A (1999) Effects of stroke localization on cardiac autonomic balance and sudden death. Stroke 30: 1307–1311
Truijllo MH, Castillo A, Espaa J, Manzo A, Zerpa R (1987) Impact of intensive care management on the prognosis of tetanus. Analysis of 641 cases. Chest 92: 63–65
Walczak TS, Leppik LE, D’Amelio M, Ravick J, So E, Ahman P, Ruggles K, Cascino GD, Annegers JF, Hauser WA (2001) Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 56: 519–525
Winer JB, Hughes RAC (1988) Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. Q J Med 257: 735–739
Wray NP, Nicotra MB (1978) Pathogenesis of pulmonary edema. Am Rev Respir Dis 118: 783–786
Zochodone DW (1994) Autonomic involvement in Guillain-Barré syndrome: a review. Muscle & Nerve 17: 1145–1155
Literatur
Adams RD, Victor M, Mancall EL (1959) Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. Arch Neurol Psychiatry 81:154–172
Ayus JC, Krothapalli RK, Arieff AI (1987) Treatment of symptomatic hyponatremia and its relation to brain damage: a prospective study. N Engl J Med 317:1190–1195
Bibl D, Lampl C, Gabriel C, Jungling G, Brock H, Köstler G (1999) Treatment of central pontine myelinolysis with therapeutic plasmapheresis. Lancet 353:1155
Brown WD (2000) Osmotic demyelinisation disorders: Central pontine and extrapontine myelinolysis. Curr Opin Neurol 13:691–697
Brunner JE, Redmond JM, Haggar AM (1990) Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Ann Neurol 27:61–66
Chemaly R, Halaby G, Mohasseb G, Medlej R, Tamraz J, El-Koussa S (1998) Extrapontine myelinolysis: Treatment with TRH. Rev Neurol 154:163–165
DeLuca GC, Nagy Z, Esiri MM, Davey P (2002) Evidence for a role for apoptosis in central pontine myelinolysis. Acra Neuropathol 103:590–598.
Finsterer J, Engelmayer E, Trnka E, Stiskal M (2000) Immunoglobulins are effective in pontine myelinolysis. Clin Neuropharmacol 23:110–113
Gocht A, Colmant HJ (1987) Central pontine and extrapontine myelinolysis: a report of 58 cases. Clin Neuropathol 6:262–270
Kabeer MH, Filio RS, Milgrom JL, Pescovitz MD, Leapman SP, Lumeng L, Jindal RM (1995) Central pontine myelinolysis following orthotopic liver transplantation: Association with cyclosporine toxicity. Postgrad Med J 71:239–241
Karp BI, Laureno R (1993) Pontine and extrapontine myelinolysis a neurologic disorder following rapid correction of hyponatremia. Medicine (Baltimore) 72:359–373
Kleinschmidt-De Masters BK, Anderson CA, Rubinstein D (1997) Asymptomatic pontine lesions found by magnetic resonance imaging: are they central pontine myelinolysis. J Neurol Sci 149: 27–35
Kleinschmidt-DeMasters BK, Rojiani AM, Filley CM (2006) Central and extrapontine Myelinolysis: Then.. and now. J Neuropathol Exp Neurol 65:1–11.
Kumar SR, Mone AP, Gray LC, Troost BT (2000) Central pontine myelinolysis: Delayed changes on neuroimaging. J Neuroimag 10:169–172
Lampl C, Kambiz Y (2002) Central pontine myelinolysis. Eur Neurol 47:3–10.
Laureno R, Karp BI (1997) Myelinolysis after correction of hyponatremia. Ann Intern Med 126:57–62
Martin PJ, Young CA (1995) Central pontine myelinolysis: clinical and MRI correlates. Postgrad Med J 71:430–432
Martin RJ (2004) Central pontine and extrapontine myelinolysis: the osmotic demyelination sysnromes. J Neurol Neurosurg Psychiatry 75(Suppl III):iii22–iii28.
McKee AC, Winkelmann MD, Banker BQ (1988) Central pontine myelinolysis in severely burned patients: relationship to serum hyperosmolality. Neurology 38:1211–1217
Menger H, Jörg J (1999) Outcome of central pontine and extrapontine myelinolysis (N=44). J Neurol 246: 700–705
Menger H, Mackowski J, Jörg J, Cramer BM (1998) Pontine und extrapontine Myelinolysen. Frühdiagnostischer und prognostischer Wert von zerebralem CT und MRT. Nervenarzt 69: 1083–1090
Norenberg MD (1983) A hypothesis of osmotic endothelial injury: A pathogenetic mechanism in central pontine myelinolysis. Arch Neurol 40:66–69
Oya S, Tsutsumi K, Ueki K et al. (2001) Reinduction of hyponatraemia to treat central pontine myelinolysis. Neurology 57:1931–1932.
Rojiani AM, Pirenas JW, Cho ES (1994) Electrolyte induced demyelinisation in rats. 1. Role of the blood-brain barrier and edema. Acta Neuropathol 88:287–292
Rojiani AM, Prineas JW, Cho ES (1987) Protective effect of steroids in electrolyte-induced demyelination. J Neuropathol Exp Neurol 46: 495–504
Sadeh M, Goldhammer Y (1993) Extrapyramidal syndrome responsive to dopaminergic treatment following recovery from central pontine myelinolysis. Eur Neurol 33: 48–50
Wright DG, Laureno R, Victor M (1979) Pontine and extrapontine myelinolysis. Brain 102:361–385
Literatur
Arnold G, Trenkwalder C, Schwarz J, Oertel WH (1994) Zotepine reversibly induces akinesia and rigidity in Parkinson’s disease patients with resting tremor or drug-induced psychosis. Mov Disord 9: 238–40.
Baratti M, Calzetti S (1984) Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 47: 1241–3.
Brandstädter D, Wächter T, Ulm G, Oertel WH (2002) Treatment of drug-induced psychosis with Quetiapine and clozapine in Parkinson’s diesease [Letter]. Neurology 58: 160–161.
Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y (1997) Lowdose clozapine improves dyskinesias in Parkinson’s disease. Neurology 48: 658–62.
Eichhorn TE, Brunt E, Oertel WH (1996) Ondansetron treatment of Ldopa-induced psychosis. Neurology 47: 1608–9.
Factor SA, Molho ES, Friedman JH (2002) Risperidone and Parkinson’s disease. Mov Disord 17: 221–2.
Friedman JH, Feinberg SS, Feldman RG (1985) A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. Jama 254: 2792–5.
Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39: 1219–21.
Goetz CG, Lutge W, Tanner CM (1986) Autonomic dysfunction in Parkinson’s disease. Neurology 36: 73–5.
Juncos JL, Roberts VJ, Evatt ML, et al. (2004) Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov Disord 19: 29–35.
Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect 6: 63–72.
Mancini F, Tassorelli C, Martignoni E, et al. (2004) Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol 27: 33–7.
Manyam BV. Uncommon forms of tremor. In: Watts RL, Koller WC, eds. Movement Disorders. Neurologic Principles and Practice. McGraw-Hill, 1997:387–403.
Morgante L, Epifanio A, Spina E, et al. (2002) Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci 23Suppl 2: S89–90.
Morgante L, Epifanio A, Spina E, et al. (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27: 153–6.
Nath A, Hobson DE, Russell A (1993) Movement Disorders with cerebral Toxoplasmosis and AIDS. Mov.Disord. 8: 107–112.
Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson’s disease—long-term experience. Acta Neurol Scand 104: 343–8.
Obeso JA, Artieda J, Quinn N, et al. (1988) Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 11: 529–36.
Oertel W, Fahn S. Parkinsonism. In: Brandt T, H.C. D, Caplan LR, C. K, Dichgans J, eds. Neurological disorders:course and treatment. San Diego: Academic Press, 2003:1021–1079.
Ozelius LJ, Hewett JW, Page CE, et al. (1997) The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 17: 40–8.
Poewe W, Kleedorfer B, Wagner M, Benke T, Gasser T, Oertel W (1989) Side-effects of subcutaneous apomorphine in Parkinson’s disease. Lancet 1: 1084–5.
Poewe WH, Oertel W. Parkinson’s disease. In: Hacke W, ed. Neuro Critical Care. Berlin: Springer Verlag, 1994:883–887.
Pollak P (2002) [Psychic disorders]. Rev Neurol (Paris) 158 Spec no 1: S125–31.
Sechi GP, Tanda F, Mutani R (1984) Fatal hyperpyrexia after withdrawal of levodopa. Neurology 34: 249–51.
Singer C, Berger JR, Bowen BC, Bruce JH, Weiner WJ (1993) Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoencephalopathy. Mov.Disord. 8: 113–116.
The Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 60: 1721–8.
Tinker R, Anderson MG, Anand P, Kermode A, Harding AE (1990) Pontine myelinolysis presenting with acute parkinsonism as a sequel of corrected hyponatraemia [letter]. J Neurol Neurosurg Psychiatry 53: 87–8.
Wijdicks EF, Parisi JE, Sharbrough FW (1994) Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol 35: 239–43.
Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 47: 1085–7.
Yamawaki Y, Ogawa N (1992) Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease. Intern Med 31: 1298–302.
Zoldan J, Friedberg G, Livneh M, Melamed E (1995) Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45: 1305–8.
Literatur
Albanese A, Hindmarsh P, Stanhope R. Management of hyponatraemia in patients with acute cerebral insults. Arch Dis Child. 2001 Sep;85(3):246–51.
Bettendorf M, Schmidt KG, Grulich-Henn J, Ulmer HE, Heinrich UE. Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study. Lancet. 2000 Aug 12;356(9229):529–34.
DeGroot LJ. «Non-thyroidal illness syndrome» is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge. J Endocrinol Invest. 2003 Dec;26(12):1163–70.
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064–2072
Harrigan MR. Cerebral salt wasting syndrome: A review. Neurosurgery. 1996;38:152–160
Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab. 2003 May–Jun;14(4):182–7.
Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999 Sep 9;341(11):785–92.
Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol. 2000 Jul;143(1):1–13.
Van den Berghe G. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol. 2002 Oct;23(4):370–91.
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359–67.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Padovan, C.S. et al. (2008). Metabolische Störungen. In: Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (eds) NeuroIntensiv. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68317-9_39
Download citation
DOI: https://doi.org/10.1007/978-3-540-68317-9_39
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23051-9
Online ISBN: 978-3-540-68317-9
eBook Packages: Medicine (German Language)